Is CBIO or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Crescent Biopharma N/A -101.50% -86.86% First Tracks Biotherapeutics N/A N/A N/A

Does the media refer more to CBIO or TRAX?

In the previous week, First Tracks Biotherapeutics had 5 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for First Tracks Biotherapeutics and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.79 beat First Tracks Biotherapeutics' score of 0.33 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive First Tracks Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CBIO or ZYME?

In the previous week, Zymeworks had 20 more articles in the media than Crescent Biopharma. MarketBeat recorded 22 mentions for Zymeworks and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.79 beat Zymeworks' score of 0.54 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media prefer ANAB or CBIO?

In the previous week, AnaptysBio had 1 more articles in the media than Crescent Biopharma. MarketBeat recorded 3 mentions for AnaptysBio and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.79 beat AnaptysBio's score of 0.63 indicating that Crescent Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SEPN or CBIO?

In the previous week, Septerna had 31 more articles in the media than Crescent Biopharma. MarketBeat recorded 33 mentions for Septerna and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.79 beat Septerna's score of 0.62 indicating that Crescent Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 6 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, CBIO or AAPG?

Crescent Biopharma has higher earnings, but lower revenue than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Crescent Biopharma $10.84M 55.44 -$153.94M -$6.72 N/A Ascentage Pharma Group International $82.10M 21.10 -$177.71M N/A N/A

Is CBIO or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Crescent Biopharma N/A -101.50% -86.86% Ascentage Pharma Group International N/A N/A N/A

Crescent Biopharma (CBIO) Competitors

$16.18 -0.45 (-2.71%)

As of 09:49 AM Eastern

Compare

CBIO vs. TRAX, ZYME, ANAB, SEPN, and AAPG

Should you buy Crescent Biopharma stock or one of its competitors? Crescent Biopharma's main competitors and comparable companies include First Tracks Biotherapeutics (TRAX), Zymeworks (ZYME), AnaptysBio (ANAB), Septerna (SEPN), and Ascentage Pharma Group International (AAPG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Crescent Biopharma compare to First Tracks Biotherapeutics?

Crescent Biopharma (NASDAQ:CBIO) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

First Tracks Biotherapeutics' return on equity of 0.00% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
First Tracks Biotherapeutics	N/A	N/A	N/A

Crescent Biopharma currently has a consensus price target of $29.40, suggesting a potential upside of 81.71%. First Tracks Biotherapeutics has a consensus price target of $60.50, suggesting a potential upside of 39.82%. Given Crescent Biopharma's higher possible upside, equities research analysts clearly believe Crescent Biopharma is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
First Tracks Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

In the previous week, First Tracks Biotherapeutics had 5 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for First Tracks Biotherapeutics and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.79 beat First Tracks Biotherapeutics' score of 0.33 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
First Tracks Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.2% of Crescent Biopharma shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

First Tracks Biotherapeutics has lower revenue, but higher earnings than Crescent Biopharma. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	55.44	-$153.94M	-$6.72	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

Summary

Crescent Biopharma beats First Tracks Biotherapeutics on 7 of the 13 factors compared between the two stocks.

How does Crescent Biopharma compare to Zymeworks?

Crescent Biopharma (NASDAQ:CBIO) and Zymeworks (NASDAQ:ZYME) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Crescent Biopharma currently has a consensus price target of $29.40, suggesting a potential upside of 81.71%. Zymeworks has a consensus price target of $40.75, suggesting a potential upside of 60.97%. Given Crescent Biopharma's higher possible upside, equities research analysts plainly believe Crescent Biopharma is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Zymeworks had 20 more articles in the media than Crescent Biopharma. MarketBeat recorded 22 mentions for Zymeworks and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.79 beat Zymeworks' score of 0.54 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Zymeworks has higher revenue and earnings than Crescent Biopharma. Zymeworks is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	55.44	-$153.94M	-$6.72	N/A
Zymeworks	$105.96M	16.95	-$81.13M	-$2.02	N/A

Crescent Biopharma has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
Zymeworks	-405.31%	-72.30%	-37.18%

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by company insiders. Comparatively, 33.5% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Crescent Biopharma has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Summary

Zymeworks beats Crescent Biopharma on 10 of the 16 factors compared between the two stocks.

How does Crescent Biopharma compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

AnaptysBio has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

AnaptysBio has higher revenue and earnings than Crescent Biopharma. AnaptysBio is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	7.12	-$13.23M	-$1.08	N/A
Crescent Biopharma	$10.84M	55.44	-$153.94M	-$6.72	N/A

In the previous week, AnaptysBio had 1 more articles in the media than Crescent Biopharma. MarketBeat recorded 3 mentions for AnaptysBio and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.79 beat AnaptysBio's score of 0.63 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AnaptysBio currently has a consensus target price of $82.00, indicating a potential upside of 45.44%. Crescent Biopharma has a consensus target price of $29.40, indicating a potential upside of 81.71%. Given Crescent Biopharma's higher possible upside, analysts clearly believe Crescent Biopharma is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

75.2% of Crescent Biopharma shares are owned by institutional investors. 31.5% of AnaptysBio shares are owned by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Crescent Biopharma has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Crescent Biopharma	N/A	-101.50%	-86.86%

Summary

AnaptysBio beats Crescent Biopharma on 9 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to Septerna?

Septerna (NASDAQ:SEPN) and Crescent Biopharma (NASDAQ:CBIO) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Septerna presently has a consensus target price of $51.33, indicating a potential upside of 13.06%. Crescent Biopharma has a consensus target price of $29.40, indicating a potential upside of 81.71%. Given Crescent Biopharma's higher possible upside, analysts clearly believe Crescent Biopharma is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Septerna has higher revenue and earnings than Crescent Biopharma. Septerna is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	46.12	-$48.88M	-$0.54	N/A
Crescent Biopharma	$10.84M	55.44	-$153.94M	-$6.72	N/A

75.2% of Crescent Biopharma shares are owned by institutional investors. 5.8% of Septerna shares are owned by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Crescent Biopharma has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.59% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.59%	-6.22%
Crescent Biopharma	N/A	-101.50%	-86.86%

Septerna has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

In the previous week, Septerna had 31 more articles in the media than Crescent Biopharma. MarketBeat recorded 33 mentions for Septerna and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.79 beat Septerna's score of 0.62 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	6 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Septerna beats Crescent Biopharma on 9 of the 16 factors compared between the two stocks.

How does Crescent Biopharma compare to Ascentage Pharma Group International?

Crescent Biopharma (NASDAQ:CBIO) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Crescent Biopharma has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

Crescent Biopharma has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	55.44	-$153.94M	-$6.72	N/A
Ascentage Pharma Group International	$82.10M	21.10	-$177.71M	N/A	N/A

Ascentage Pharma Group International's return on equity of 0.00% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
Ascentage Pharma Group International	N/A	N/A	N/A

Crescent Biopharma currently has a consensus price target of $29.40, indicating a potential upside of 81.71%. Ascentage Pharma Group International has a consensus price target of $46.43, indicating a potential upside of 150.29%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

In the previous week, Ascentage Pharma Group International had 3 more articles in the media than Crescent Biopharma. MarketBeat recorded 5 mentions for Ascentage Pharma Group International and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.79 beat Ascentage Pharma Group International's score of 0.20 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

75.2% of Crescent Biopharma shares are owned by institutional investors. 24.8% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Ascentage Pharma Group International beats Crescent Biopharma on 8 of the 14 factors compared between the two stocks.

Get Crescent Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBIO vs. The Competition

Export

Metric	Crescent Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$600.93M	$3.75B	$7.07B	$13.00B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-2.41	10.24	269.63	25.21
Price / Sales	55.44	1,291.29	596.70	99.90
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	3.77	17.68	13.11	6.24
Net Income	-$153.94M	-$13.30M	$3.45B	$347.70M
7 Day Performance	-3.92%	0.66%	0.77%	0.87%
1 Month Performance	5.68%	0.51%	1.44%	0.90%
1 Year Performance	16.15%	54.56%	67.07%	20.13%

Crescent Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBIO Crescent Biopharma	3.1573 of 5 stars	$16.18 -2.7%	$29.40 +81.7%	+19.6%	$600.93M	$10.84M	N/A	50
TRAX First Tracks Biotherapeutics	3.7309 of 5 stars	$46.01 -0.3%	$47.88 +4.1%	N/A	$1.61B	N/A	N/A	N/A	News Coverage Earnings Report Analyst Forecast
ZYME Zymeworks	2.2199 of 5 stars	$22.79 +4.5%	$37.33 +63.8%	+84.8%	$1.59B	$105.96M	N/A	460	Earnings Report Analyst Revision
ANAB AnaptysBio	2.26 of 5 stars	$55.20 +2.9%	$82.00 +48.6%	+170.4%	$1.59B	$234.60M	N/A	100
SEPN Septerna	1.7495 of 5 stars	$38.98 +11.4%	$45.89 +17.7%	+286.1%	$1.58B	$45.95M	N/A	N/A	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBIO) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crescent Biopharma (CBIO) Competitors

CBIO vs. TRAX, ZYME, ANAB, SEPN, and AAPG

How does Crescent Biopharma compare to First Tracks Biotherapeutics?

Summary

How does Crescent Biopharma compare to Zymeworks?

Summary

How does Crescent Biopharma compare to AnaptysBio?

Summary

How does Crescent Biopharma compare to Septerna?

Summary

How does Crescent Biopharma compare to Ascentage Pharma Group International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crescent Biopharma (CBIO) Competitors

CBIO vs. TRAX, ZYME, ANAB, SEPN, and AAPG

How does Crescent Biopharma compare to First Tracks Biotherapeutics?

Is CBIO or TRAX more profitable?

Do analysts rate CBIO or TRAX?

Does the media refer more to CBIO or TRAX?

Do insiders & institutionals believe in CBIO or TRAX?

Which has higher earnings & valuation, CBIO or TRAX?

Summary

How does Crescent Biopharma compare to Zymeworks?

Do analysts recommend CBIO or ZYME?

Does the media refer more to CBIO or ZYME?

Which has stronger valuation and earnings, CBIO or ZYME?

Is CBIO or ZYME more profitable?

Do institutionals and insiders hold more shares of CBIO or ZYME?

Which has more volatility and risk, CBIO or ZYME?

Summary

How does Crescent Biopharma compare to AnaptysBio?

Which has more volatility & risk, ANAB or CBIO?

Which has better earnings and valuation, ANAB or CBIO?

Does the media prefer ANAB or CBIO?

Do analysts prefer ANAB or CBIO?

Do insiders & institutionals believe in ANAB or CBIO?

Is ANAB or CBIO more profitable?

Summary

How does Crescent Biopharma compare to Septerna?

Do analysts rate SEPN or CBIO?

Which has preferable valuation & earnings, SEPN or CBIO?

Do insiders & institutionals believe in SEPN or CBIO?

Is SEPN or CBIO more profitable?

Which has more volatility and risk, SEPN or CBIO?

Does the media prefer SEPN or CBIO?

Summary

How does Crescent Biopharma compare to Ascentage Pharma Group International?

Which has more volatility & risk, CBIO or AAPG?

Which has better valuation & earnings, CBIO or AAPG?

Is CBIO or AAPG more profitable?

Do analysts recommend CBIO or AAPG?

Does the media favor CBIO or AAPG?

Do institutionals & insiders have more ownership in CBIO or AAPG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools